The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

The Washington Post editorial board argued a federal judge's ruling against congressional Medicaid restrictions on abortion ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

Republican National Committee Chairman Michael Whatley has launched his campaign for North Carolina’s open U.S. Senate seat ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.